iOX Therapeutics Ltd. logo

iOX Therapeutics Ltd.

Iox Therapeutics is a spin out from Ludwig Cancer Research, developing a new type of immunotherapy agents invariant natural killer T-cells (iNKT cells) agonists designed to target cancer.

iOx is further developing novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Prof. Vincenzo Cerundolo, Director of MRC Human Immunology Unit within the University of Oxfords Weatherall Institute of Molecular Medicine.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.salvarx.io
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
The Broadgate Tower 8th Floor 20 Primrose Street, EC2A 2EW England
London
United Kingdom
Email
Contact Number
+1 203-221-7378

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=https://www.linkedin.com/company/iox-therapeutics-limited
“” connections=”true” suffix=””]

iOx is working on multiple synthetic lipid compounds, that activate iNKT cells. Recent evidence suggests that iNKT cells play an important role in anti-tumour immune responses and could prove highly effective in combination with other immunotherapies.

In 2015, iOx Therapeutics recieved its seed funding from SalvaRx Group, founded by Drs. Ian Walters and Rob Kramer, two former Bristol-Myers Squibb drug developers with a history of developing immune-oncology therapeutics.